Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig.4.L-O,V
Tavares ALP et al. (2021)
|
Xla Wt + sobp
NF16-18 (in situ hybridization)
|
|
|
|
Fig.4.B
Tavares ALP et al. (2021)
|
Xla Wt + sobp
NF16-18 (RT-PCR)
|
|
|
|
Fig.4.H-K,U
Tavares ALP et al. (2021)
|
Xla Wt + sobp CRISPR
NF16-18 (in situ hybridization)
|
|
|
|
Fig.4.D-G,T
Tavares ALP et al. (2021)
|
Xla Wt + sobp MO
NF16-18 (in situ hybridization)
|
|
|
|
Fig.4.Q-S,X
Tavares ALP et al. (2021)
|
Xla Wt + sobpR651X
NF16-18 (in situ hybridization)
|
|
|
|
Fig.4.C
Tavares ALP et al. (2021)
|
Xla Wt + sobpR651X
NF16-18 (RT-PCR)
|
|
|
|
Fig. 3
Virgirinia RP et al. (2021)
|
Xla Wt + clk1
NF21 (RT-PCR)
|
|
|
|
Fig. 3
Virgirinia RP et al. (2021)
|
Xla Wt + clk2
NF21 (RT-PCR)
|
|
|
|
Fig. 3
Virgirinia RP et al. (2021)
|
Xla Wt + clk3
NF21 (RT-PCR)
|
|
|
|
Fig.6.F
Chen M et al. (2020)
|
Xla Wt + tmem79 MO
NF16 (in situ hybridization)
|
|
|